RecruitingNot ApplicableNCT06735001

Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention

Sponsor

University Hospital, Bordeaux

Enrollment

400 participants

Start Date

Mar 10, 2025

Study Type

INTERVENTIONAL

Conditions

Atrial Fibrillation (AF)

Summary

Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether the blood's chemical makeup (metabolic profile) in patients with atrial fibrillation — an irregular heartbeat — is different from people without it, and whether these differences can help predict who might develop the condition. **You may be eligible if...** - You are 18 years of age or older (any gender or ethnic background) - You have given or are willing to give written consent to participate - You are covered by a social security scheme (France-based) **You may NOT be eligible if...** - You are pregnant - You are under legal protection or guardianship - You have active endocarditis or pericarditis (heart lining infections) in the past 3 months - You have an active tumor, chronic inflammation, or an autoimmune disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.